Seeking Alpha

Report: Merck explores $15B drug portfolio sale

  • Merck (MRK) is considering the potential sale of a portfolio of off-patent drugs which could command more than $15B, Reuters reports.
  • MRK, which also is in the process of selling its $14B consumer healthcare unit, is said to be working with an investment bank on the potential sale of the portfolio of mature drugs, which could draw interest from generic drugmakers.
  • The sale process would underscore efforts by large drugmakers to shed smaller divisions they view as non-core so they can better focus on their mainstay products.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs